4//SEC Filing
Mehta Vimal 4
Accession 0001104659-24-129462
CIK 0001720893other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 6:08 PM ET
Size
17.3 KB
Accession
0001104659-24-129462
Insider Transaction Report
Form 4
Mehta Vimal
DirectorCEO and President
Transactions
- Sale
Common Stock
2024-12-16$0.36/sh−983$358→ 60,920 total - Exercise/Conversion
Common Stock
2024-12-14+2,610→ 58,403 total - Exercise/Conversion
Restricted Stock Units
2024-12-15−3,500→ 31,500 total→ Common Stock (3,500 underlying) - Exercise/Conversion
Common Stock
2024-12-15+3,500→ 61,903 total - Sale
Common Stock
2024-12-16$0.36/sh−2,134$773→ 59,605 total - Exercise/Conversion
Restricted Stock Units
2024-12-14−2,610→ 13,049 total→ Common Stock (2,610 underlying)
Holdings
- 7,685,501(indirect: By LLC)
Common Stock
- 2,000(indirect: By Spouse)
Common Stock
Footnotes (6)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023.
- [F3]The price reported is a weighted average price. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
- [F5]On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F6]On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Documents
Issuer
BioXcel Therapeutics, Inc.
CIK 0001720893
Entity typeother
Related Parties
1- filerCIK 0001733369
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 6:08 PM ET
- Size
- 17.3 KB